MicroRNAs associated with therapy of non-small cell lung cancer
暂无分享,去创建一个
S. Fan | Jiadi Luo | Yuting Zhan | Juan Feng | Junmi Lu
[1] S. Fan,et al. Roles of microRNAs in the resistance to platinum based chemotherapy in the non-small cell lung cancer , 2017, Journal of Cancer.
[2] Baoli Hu,et al. miR-181c contributes to cisplatin resistance in non-small cell lung cancer cells by targeting Wnt inhibition factor 1 , 2017, Cancer Chemotherapy and Pharmacology.
[3] Jifeng Feng,et al. MicroRNA-106b-5p regulates cisplatin chemosensitivity by targeting polycystic kidney disease-2 in non-small-cell lung cancer , 2017, Anti-cancer drugs.
[4] S. Fan,et al. Long non-coding RNAs associated with non-small cell lung cancer , 2017, Oncotarget.
[5] Zhengxiang Shan,et al. MicroRNA-92a promotes epithelial-mesenchymal transition through activation of PTEN/PI3K/AKT signaling pathway in non-small cell lung cancer metastasis. , 2017, International journal of oncology.
[6] Li-na Peng,et al. miR-181b-5p mediates TGF-β1-induced epithelial-to-mesenchymal transition in non-small cell lung cancer stem-like cells derived from lung adenocarcinoma A549 cells , 2017, International journal of oncology.
[7] C. Gridelli,et al. Real-world treatment patterns for patients receiving second-line and third-line treatment for advanced non-small cell lung cancer: A systematic review of recently published studies , 2017, PloS one.
[8] F. Alongi,et al. Stage-I small cell lung cancer: A new potential option for stereotactic ablative radiation therapy? A review of literature. , 2017, Critical reviews in oncology/hematology.
[9] A. Nielsen,et al. MET amplification and epithelial-to-mesenchymal transition exist as parallel resistance mechanisms in erlotinib-resistant, EGFR-mutated, NSCLC HCC827 cells , 2017, Oncogenesis.
[10] Guan-Jhong Huang,et al. 3,4-Dihydroxybenzalactone Suppresses Human Non-Small Cell Lung Carcinoma Cells Metastasis via Suppression of Epithelial to Mesenchymal Transition, ROS-Mediated PI3K/AKT/MAPK/MMP and NFκB Signaling Pathways , 2017, Molecules.
[11] N. Villegas-Sepúlveda,et al. Tumor suppressor miR-29c regulates radioresistance in lung cancer cells , 2017, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine.
[12] Gang Chen,et al. Clinical value of miR-145-5p in NSCLC and potential molecular mechanism exploration: A retrospective study based on GEO, qRT-PCR, and TCGA data , 2017, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine.
[13] Shuxu Zhang,et al. Disturbance of the let-7/LIN28 double-negative feedback loop is associated with radio- and chemo-resistance in non-small cell lung cancer , 2017, PloS one.
[14] Yanjing Wang,et al. Up-regulation of miR-146a increases the sensitivity of non-small cell lung cancer to DDP by downregulating cyclin J , 2017, BMC Cancer.
[15] Hongbing Shen,et al. Downregulation of miR-218 contributes to epithelial–mesenchymal transition and tumor metastasis in lung cancer by targeting Slug/ZEB2 signaling , 2017, Oncogene.
[16] Sze Chuen Cesar Wong,et al. MiR-30 Family Potentially Targeting PI3K-SIAH2 Predicted Interaction Network Represents a Novel Putative Theranostic Panel in Non-small Cell Lung Cancer , 2017, Frontiers in genetics.
[17] Xiao-Feng Li,et al. Suppression of EIF4G2 by miR‐379 potentiates the cisplatin chemosensitivity in nonsmall cell lung cancer cells , 2017, FEBS letters.
[18] S. Fan,et al. The role of microRNAs in resistance to targeted treatments of non-small cell lung cancer , 2017, Cancer Chemotherapy and Pharmacology.
[19] Jinmei Li,et al. miR-135b reverses chemoresistance of non-small cell lung cancer cells by downregulation of FZD1. , 2016, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
[20] Bin Zhou,et al. Pathologically decreased expression of miR-193a contributes to metastasis by targeting WT1-E-cadherin axis in non-small cell lung cancers , 2016, Journal of experimental & clinical cancer research : CR.
[21] E. Buratti,et al. Circulating Plasma MicroRNAs As Diagnostic Markers for NSCLC , 2016, Front. Genet..
[22] L. Pan,et al. MiR-21 and MiR-155 promote non-small cell lung cancer progression by downregulating SOCS1, SOCS6, and PTEN , 2016, Oncotarget.
[23] Dejia Li,et al. The Novel miR-9600 Suppresses Tumor Progression and Promotes Paclitaxel Sensitivity in Non–small-cell Lung Cancer Through Altering STAT3 Expression , 2016, Molecular therapy. Nucleic acids.
[24] Wei Liu,et al. miR-200c regulates crizotinib-resistant ALK-positive lung cancer cells by reversing epithelial-mesenchymal transition via targeting ZEB1 , 2016, Molecular medicine reports.
[25] D. Goldstein,et al. Next-generation EGFR/HER tyrosine kinase inhibitors for the treatment of patients with non-small-cell lung cancer harboring EGFR mutations: a review of the evidence , 2016, OncoTargets and therapy.
[26] Zhang Jx,et al. MicroRNA-132 inhibits migration, invasion and epithelial-mesenchymal transition by regulating TGFβ1/Smad2 in human non-small cell lung cancer. , 2016, European review for medical and pharmacological sciences.
[27] L. Ling,et al. miR-143 suppresses the proliferation of NSCLC cells by inhibiting the epidermal growth factor receptor. , 2016, Experimental and therapeutic medicine.
[28] Wei Ma,et al. Up- regulation of miR-328-3p sensitizes non-small cell lung cancer to radiotherapy , 2016, Scientific Reports.
[29] N. Seki,et al. MicroRNAs in non-small cell lung cancer and idiopathic pulmonary fibrosis , 2016, Journal of Human Genetics.
[30] Wei Zhang,et al. Attenuated LKB1-SIK1 signaling promotes epithelial-mesenchymal transition and radioresistance of non–small cell lung cancer cells , 2016, Chinese journal of cancer.
[31] Baosheng Li,et al. miR‐134 inhibits non‐small cell lung cancer growth by targeting the epidermal growth factor receptor , 2016, Journal of cellular and molecular medicine.
[32] Ming Liu,et al. MicroRNA-21 Regulates Non-Small Cell Lung Cancer Cell Invasion and Chemo-Sensitivity through SMAD7 , 2016, Cellular Physiology and Biochemistry.
[33] Dong Chen,et al. MicroRNA-21 modulates radiation resistance through upregulation of hypoxia-inducible factor-1α-promoted glycolysis in non-small cell lung cancer cells. , 2016, Molecular medicine reports.
[34] F. Ciardiello,et al. Mechanisms of resistance to EGFR-targeted drugs: lung cancer , 2016, ESMO Open.
[35] J. Neuzil,et al. MicroRNA-126 induces autophagy by altering cell metabolism in malignant mesothelioma , 2016, Oncotarget.
[36] Wei Zhang,et al. miRNA-296-3p modulates chemosensitivity of lung cancer cells by targeting CX3CR1. , 2016, American journal of translational research.
[37] Xiaoju Wang,et al. MiR-1244 sensitizes the resistance of non-small cell lung cancer A549 cell to cisplatin , 2016, Cancer Cell International.
[38] Ya‐Wen Cheng,et al. Reduction of microRNA-184 by E6 oncoprotein confers cisplatin resistance in lung cancer via increasing Bcl-2 , 2016, Oncotarget.
[39] H. Bai,et al. Clinical outcomes of EGFR-TKI treatment and genetic heterogeneity in lung adenocarcinoma patients with EGFR mutations on exons 19 and 21 , 2016, Chinese journal of cancer.
[40] Jinchao Zhang,et al. Triptolide reduces proliferation and enhances apoptosis of human non-small cell lung cancer cells through PTEN by targeting miR-21. , 2016, Molecular medicine reports.
[41] Hong Zhang,et al. MicroRNA-92a promotes growth, metastasis, and chemoresistance in non-small cell lung cancer cells by targeting PTEN , 2016, Tumor Biology.
[42] Li-na Peng,et al. miR-223 reverses the resistance of EGFR-TKIs through IGF1R/PI3K/Akt signaling pathway , 2016, International journal of oncology.
[43] W. Cho,et al. Implications of MicroRNAs in the Treatment of Gefitinib-Resistant Non-Small Cell Lung Cancer , 2016, International journal of molecular sciences.
[44] M. Zhong,et al. Inhibition of microRNA-196a might reverse cisplatin resistance of A549/DDP non-small-cell lung cancer cell line , 2016, Tumor Biology.
[45] He Xiao,et al. EGFR mutation status in plasma and tumor tissues in non-small cell lung cancer serves as a predictor of response to EGFR-TKI treatment , 2016, Cancer biology & therapy.
[46] Qinghua Zhou,et al. MicroRNA-338-3p suppresses metastasis of lung cancer cells by targeting the EMT regulator Sox4. , 2016, American journal of cancer research.
[47] Zhongzhen Su,et al. Downregulation of miR-101 contributes to epithelial-mesenchymal transition in cisplatin resistance of NSCLC cells by targeting ROCK2 , 2016, Oncotarget.
[48] Yan-bin Zhao,et al. MiR-181b regulates cisplatin chemosensitivity and metastasis by targeting TGFβR1/Smad signaling pathway in NSCLC , 2015, Scientific Reports.
[49] Jun Yin,et al. The regulatory and predictive functions of miR-17 and miR-92 families on cisplatin resistance of non-small cell lung cancer , 2015, BMC Cancer.
[50] M. Huang,et al. Knockdown of microRNA-1323 restores sensitivity to radiation by suppression of PRKDC activity in radiation-resistant lung cancer cells. , 2015, Oncology reports.
[51] Rui Hu,et al. miR-106a promotes growth and metastasis of non-small cell lung cancer by targeting PTEN. , 2015, International journal of clinical and experimental pathology.
[52] Lifang Yang,et al. microRNA-548l is involved in the migration and invasion of non-small cell lung cancer by targeting the AKT1 signaling pathway , 2015, Journal of Cancer Research and Clinical Oncology.
[53] B. Xiao,et al. miR-25 modulates NSCLC cell radio-sensitivity through directly inhibiting BTG2 expression. , 2015, Biochemical and biophysical research communications.
[54] Shi-huan Yu,et al. miR‐99a Suppresses the Metastasis of Human Non‐Small Cell Lung Cancer Cells by Targeting AKT1 Signaling Pathway , 2015, Journal of cellular biochemistry.
[55] Jie Gu,et al. MicroRNA-7 sensitizes non-small cell lung cancer cells to paclitaxel , 2014, Oncology letters.
[56] G. Calin,et al. Therapeutic delivery of miR-200c enhances radiosensitivity in lung cancer. , 2014, Molecular therapy : the journal of the American Society of Gene Therapy.
[57] B. Jiang,et al. Alteration in Mir-21/PTEN Expression Modulates Gefitinib Resistance in Non-Small Cell Lung Cancer , 2014, PloS one.
[58] N. Zhong,et al. Downregulation of PEBP4, a target of miR-34a, sensitizes drug-resistant lung cancer cells , 2014, Tumor Biology.
[59] Jianjun Chen,et al. MicroRNAs in cancer biology and therapy: Current status and perspectives , 2014, Genes & diseases.
[60] W. De,et al. Acquisition of radioresistance in docetaxel-resistant human lung adenocarcinoma cells is linked with dysregulation of miR-451/c-Myc-survivin/rad-51 signaling , 2014, Oncotarget.
[61] Junjiang Fu,et al. Epithelial to mesenchymal transition inducing transcription factors and metastatic cancer , 2014, Tumor Biology.
[62] Jun Yin,et al. miRNA 17 Family Regulates Cisplatin-Resistant and Metastasis by Targeting TGFbetaR2 in NSCLC , 2014, PloS one.
[63] W. Guo,et al. Up-regulation of microRNA-138 induce radiosensitization in lung cancer cells , 2014, Tumor Biology.
[64] Wen-rong Gong,et al. miR-205 promotes the growth, metastasis and chemoresistance of NSCLC cells by targeting PTEN. , 2013, Oncology reports.
[65] A. Gemma,et al. MiR-134/487b/655 Cluster Regulates TGF-β–Induced Epithelial–Mesenchymal Transition and Drug Resistance to Gefitinib by Targeting MAGI2 in Lung Adenocarcinoma Cells , 2013, Molecular Cancer Therapeutics.
[66] G. Yousef,et al. Clinical evaluation of microRNA expression profiling in non small cell lung cancer. , 2013, Lung cancer.
[67] K. Seong,et al. Rhamnetin and Cirsiliol Induce Radiosensitization and Inhibition of Epithelial-Mesenchymal Transition (EMT) by miR-34a-mediated Suppression of Notch-1 Expression in Non-small Cell Lung Cancer Cell Lines* , 2013, The Journal of Biological Chemistry.
[68] E. Chuang,et al. MicroRNA-449a Enhances Radiosensitivity in CL1-0 Lung Adenocarcinoma Cells , 2013, PloS one.
[69] A. Noël,et al. MiR-210 promotes a hypoxic phenotype and increases radioresistance in human lung cancer cell lines , 2013, Cell Death and Disease.
[70] A. Soltermann,et al. Epithelial-mesenchymale Transition beim nichtkleinzelligen Bronchialkarzinom , 2012, Der Pathologe.
[71] Yu Zhang,et al. SOX4 induces epithelial-mesenchymal transition and contributes to breast cancer progression. , 2012, Cancer research.
[72] J. Sun,et al. EGFR and MET receptor tyrosine kinase-altered microRNA expression induces tumorigenesis and gefitinib resistance in lung cancers , 2011, Nature Medicine.
[73] N. Matsuura,et al. Epithelial to mesenchymal transition is a determinant of sensitivity to chemoradiotherapy in non-small cell lung cancer. , 2011, The Annals of thoracic surgery.
[74] Xi Chen,et al. Serum microRNA signatures identified in a genome-wide serum microRNA expression profiling predict survival of non-small-cell lung cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[75] M. Tsao,et al. Overview of molecular testing in non-small-cell lung cancer: mutational analysis, gene copy number, protein expression and other biomarkers of EGFR for the prediction of response to tyrosine kinase inhibitors , 2009, Oncogene.
[76] James B. Mitchell,et al. Ionizing Radiation-Induced Oxidative Stress Alters miRNA Expression , 2009, PloS one.
[77] A. Schetter,et al. MiR-21 is an EGFR-regulated anti-apoptotic factor in lung cancer in never-smokers , 2009, Proceedings of the National Academy of Sciences.
[78] Joon-Oh Park,et al. MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling , 2007, Science.
[79] R. Wilson,et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[80] C. Croce,et al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[81] Hao Jiang,et al. miR-200c enhances sensitivity of drug-resistant non-small cell lung cancer to gefitinib by suppression of PI3K/Akt signaling pathway and inhibites cell migration via targeting ZEB1. , 2017, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
[82] Zhu Jin,et al. MicroRNA-138 regulates chemoresistance in human non-small cell lung cancer via epithelial mesenchymal transition. , 2016, European review for medical and pharmacological sciences.
[83] Liang Han,et al. MicroRNA-155 expression has prognostic value in patients with non-small cell lung cancer and digestive system carcinomas. , 2013, Asian Pacific journal of cancer prevention : APJCP.